Browse News
Filter News
Found 8,016 articles
-
Seraxis Announces Closing of Second VC Tranche and Successful Completion of Preclinical Studies of Pancreatic Organoids From Seraxis’ Novel Pancreas-Derived Stem Cells
9/21/2023
Seraxis Inc today announced the closing of the second tranche of its inaugural VC round to bring total equity investment in the company to over $50 million.
-
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
9/21/2023
Lynk Pharmaceuticals Co., Ltd. today announced the successful completion of Series C2 financing.
-
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II
9/21/2023
Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced a term sheet to enter into a definitive business combination, which was entered into on September 18, 2023.
-
After a sluggish start to the year, experts expect an uptick in IPO offerings moving into fall, although it’s unlikely 2023 will fully shrug off its slump.
-
Cayman Chemical Receives CEP for Latanoprost API from EDQM
9/19/2023
Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients
-
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/19/2023
RayzeBio, Inc. (Nasdaq: RYZB) today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share.
-
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
-
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
-
Vaccitech recently expanded from the U.K. to the U.S. CEO Bill Enright explains why.
-
Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma
9/13/2023
Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Gabrail Cancer Center (GCC) in Canton, Ohio as the first site activated in the STAR-LLD Phase 1b clinical trial.
-
Likarda Announces Core Shell Spherification for Large Molecule Biologics and Welcomes New CEO, Dr. Stella Vnook
9/13/2023
Likarda, LLC, a pioneering cell therapy company, is at the forefront of creating advanced delivery systems that enhance the efficacy of cell therapies and new hire Dr. Stella Vnook as CEO.
-
Following a $540 million IPO in May, Acelyrin’s lead candidate izokibep failed to meet the primary endpoint in a Phase IIb/III study of patients with the chronic inflammatory skin condition.
-
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
9/12/2023
4D Molecular Therapeutics, a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT.
-
Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference
9/12/2023
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Cantor Fitzgerald Global Healthcare Conference, which takes place September 26 – 28, 2023 in New York, New York.
-
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
9/11/2023
Palisade Bio, Inc., a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer.
-
Shockwave Medical Announces Dan Puckett to Retire as CFO in 2024
9/11/2023
Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced that Chief Financial Officer Dan Puckett plans to retire in the first quarter of 2024.
-
Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million
9/6/2023
Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.
-
Izotropic Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices
9/6/2023
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView
-
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
9/6/2023
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, is pleased to announce a change of its corporate name to Scinai Immunotherapeutics Ltd.
-
IPA Announces Board Refreshment
9/5/2023
IPA, an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.